NCT04052594已完成1 期
A Randomized, Double-Blind, Single Dose, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3475766
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 3
- 主要终点
- Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
研究概览
简要总结
This study will evaluate the safety and tolerability of LY3475766 when given to participants with high levels of blood fat called triglycerides. It will also investigate how the body processes the study drug and the effect of the study drug on the body. Information about any side effects will be documented. This study will last up to 16 weeks for each participant.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Are overtly healthy males or females, apart from dyslipidemia
- •Male participants must agree to adhere to contraception restrictions
- •Female participants must be of nonchildbearing potential and include those who are infertile due to surgical sterilization or those who are postmenopausal
- •Have a body mass index (BMI) >18.5 and <40 kilograms per meter squared (kg/m²)
- •Have clinical laboratory test results within normal reference range, or acceptable deviations per investigator discretion
- •Have a fasting triglyceride (TG) level that is 135 to 499 milligrams per deciliter (mg/dL), inclusive, at both screening and Day -1
- •Have a fasting low density lipoprotein cholesterol (LDL-C) level greater than or equal to (≥) 70 mg/dL, inclusive, at screening and Day -1
- •Have had a stable body weight for the 3 months prior to randomization (<5% body weight change)
- •Have not modified diet or adopted any nutritional lifestyle modification within 3 months prior to randomization
排除标准
- •Are taking or have started taking Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors within 3 months prior to randomization; or statins, fibrates, or niacin ≤1000 mg/day within 8 weeks prior to randomization; or niacin >1000 milligrams per day (mg/day) within 16 weeks prior to randomization; or any other lipid-lowering agents within 1 month prior to randomization
- •Are taking or have started taking a beta-blocker, antiarrhythmic, non-dihydropyridine calcium channel blocker, ivabradine, or any other heart rate lowering agent within 1 month or 5 half-lives prior to randomization, whichever is longer
- •Have a diagnosis of diabetes mellitus (type 1 diabetes mellitus or type 2 diabetes mellitus) or have 1 of the following at screening: fasting plasma glucose concentration ≥126 mg/dL (7.0 millimoles per liter [mmol/L]) OR a glycated hemoglobin level ≥6.5% (48 millimoles per mole [mmol/mol])
- •Have previously completed or withdrawn from this study or any other study investigating LY3475766, and have previously received the investigational product
- •Have known allergies to LY3475766, related compounds, or any components of the formulation, or history of significant atopy
- •Have a seated heart rate ≤50 beats per minute
- •Have clinically significant abnormal electrocardiogram (ECG) results constituting a risk while taking the investigational product, as determined by the investigator
- •Have an abnormal blood pressure (BP) as determined by the investigator
研究组 & 干预措施
LY3475766 - IV
Experimental
LY3475766 administered intravenously (IV) to participants with dyslipidemia
干预措施: LY3475766 - IV (Drug)
Placebo - IV
Placebo Comparator
Placebo administered IV to participants with dyslipidemia
干预措施: Placebo - IV (Drug)
LY3475766 - SC
Experimental
LY3475766 administered subcutaneously (SC) to participants with dyslipidemia
干预措施: LY3475766 - SC (Drug)
Placebo - SC
Placebo Comparator
Placebo administered SC to participants with dyslipidemia
干预措施: Placebo - SC (Drug)
结局指标
主要结局
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
时间窗: Baseline up to Day 85
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
次要结局
- PK: Maximum Observed Drug Concentration (Cmax) of LY3475766(Predose up to Day 85)
- Pharmacodynamics (PD): Percent Change from Baseline in Triglycerides (TG)(Baseline, Day 85)
- Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3475766(Predose up to Day 85)
- PK: Time to Maximum Observed Drug Concentration (Tmax) of LY3475766(Predose up to Day 85)
- PD: Percent Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)(Baseline, Day 85)
- PD: Percent Change from Baseline in Apolipoprotein B (ApoB)(Baseline, Day 85)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730 in Healthy ParticipantsHealthy ParticipantsNCT03451890Eisai Inc.32
Unknown
1 期
Tolerability, Safety and Pharmacokinetic Study Of Mianhuahua Flavonoids Tablets in Healthy Adult SubjectsHealthyNCT02622230Xinjiang Uygur Pharmaceutical Co., Ltd.60
已完成
1 期
A Study of NKTR-358 (LY3471851) in Healthy ParticipantsHealthyNCT04380324Nektar Therapeutics100
已完成
1 期
Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy VolunteersHealthyNCT02572349Cyclerion Therapeutics24
终止
2 期
A Study of LY3127804 in Participants With COVID-19COVID-19PneumoniaNCT04342897Eli Lilly and Company95